WT1在子宫内膜腺癌中的表达及其临床意义#br#

Abstract
Figure/Table
References (0)
Related Citation (0)

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To detect the protein and gene expression of WT1 in different types of tissues, including endometrial adenocarcinoma (EA) tissues, endometrial hyperplasia tissues and normal tissues and correlated the expression with the clinicopathological features. Methods: The relative expression WT1 mRNA was detected by real-time quantitative PCR. The expression of WT1 protein was detected by Western blot in different types of endometrial tissues. Results: The expression of WT1 mRNA and protein in endometrial adenocarcinoma tissue was significantly higher than that in endometrial hyperplasia tissues and normal endometrial tissue respectively (P<0.01). There was no significant difference among age, menopause status, clinical stage, lymph node metastasis status, ER, BMI except histological stage, myometrial invasion and PR status concerned to WT1 gene expression (P<0.05). There were no significant correlations among the protein expressionof WT1 and age, menopause status, clinical stage, myometrial invasion ER, PR, BMI (P>0.05), but related to histological stage and lymph node status, significantly (P<0.05). Conclusion: Up-regulation of WT1 protein and gene expression are correlated to the oncogenesis and progression of EA.

Key words： WT1 endometrial carcinoma real-time quantitative PCR Western blot

Received: 06 June 2013

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	JIN Weiwei1
	CAI Pingsheng1
	ZHAO Xiaoying1
	ZHENG Feiyun2.

URL:

https://xb.wmu.edu.cn/EN/ OR https://xb.wmu.edu.cn/EN/Y2014/V44/I10/743

[1]Bourkoula K, Englert C, Giaisi M, et al. The Wilms’ tumor suppressor WT1 enhances CD95L expression and promotes activation-induced cell death in leukemic T cells[J]. Int J Cancer, 2014, 134(2): 291-300.
[2]Ujj Z, Buglyo G, Udvardy M, et al. WT1 overexpression affecting clinical outcome in non-hodgkin lymphomas and adult acute lymphoblastic leukemia[J]. Pathol Oncol Res, 2014, 20(3): 565-570.
[3]Uesugi K, Hiasa Y, Tokumoto Y, et al. Wilms’ tumor 1 gene modulates Fas-related death signals and anti-apoptotic functions in hepatocellular carcinoma[J]. J Gastroenterol, 2013, 48(9): 1069-1080.
[4]Sangkhathat S, Kanngurn S, Chaiyapan W, et al. Wilms’ tumor 1 gene (WT1) is overexpressed and provides an onco-genic function in pediatric nephroblastomas harboring the wild-type WT1[J]. Oncol Lett, 2010, 1(4): 615-619.
[5]Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta CT method[J]. Methods, 2001, 25(4): 402-408.
[6]Wang X, Gao P, Lin F, et al. Wilms’ tumour suppressor gene1 (WT1) is involved in the carcinogenesis of Lung cancer through interaction with PI3K/Akt pathway[J]. Cancer Cell Int, 2013, 13(1): 114.
[7]Scattone A, Serio G, Marzullo A, et al. High Wilms’ tumour gene (WT1) expression and low mitotic count are independent predictors of survival in diffuse peritoneal mesothelio-ma[J]. Histopathology, 2012, 60(3): 472-481.
[8]Liu Z, Yamanouchi K, Ohtao T, et al. High levels of Wilms’ tumor 1 (WT1) expression were associated with aggressive clinical features in ovarian cancer[J]. Anticancer Res, 2014, 34(5): 2331-2340.
[9]Hwang H, Quenneville L, Yaziji H, et al. Wilms tumor gene product: sensitive and contextually specific marker of serous carcinomas of ovarian surface epithelial origin[J]. Appl Im-munohistochem Mol Morphol, 2004, 12(2): 122-126.
[10]Andersson C, Oji Y, Ohlson N, et al. Prognostic significance of specific anti-WT1 IgG antibody level in plasma in patients with ovarian carcinoma[J]. Cancer Med, 2014, 3(4): 909-918.
[11]Dohi S, Ohno S, Ohno Y, et al. WT1 expression correlates with angiogenesis in endometrial cancer tissue[J]. Antican-cer Res, 2010, 30(8): 3187-3192.
[12]Matalka I, Obeidat B, Mohtaseb A, et al. The significance of Wilms Tumor Gene (WT1) and p53 expression in curettage specimens of patients with endometrial carcinomas[J]. Pathol Res Pract, 2013, 209(1): 19-23.
[13]Ohno S, Dohi S, Ohno Y, et al. Immunohistochemical de-tection of WT1 protein in endometrial cancer[J]. Anticancer Res, 2009, 29(5): 1691-1695.
[14]Nakatsuka S, Oji Y, Horiuchi T, et al. Immunohistochemi-cal detection of WT1 protein in a variety of cancer cells[J].Mod Pathol, 2006, 19(6): 804-814.
[15]Oji Y, Kitamura Y, Kamino E, et al. WT1 IgG antibody for early detection of nonsmall cell lung cancer and as its prog-nostic factor[J]. Int J Cancer, 2009, 125(2): 381-387.
[16]Choi EJ, Yun JA, Jeon EK, et al. Prognostic significance of RSPO1, WNT1, P16, WT1, and SDC1 expressions in inva-sive ductal carcinoma of the breast[J]. World J Surg Oncol, 2013, 11: 314.
[17]Huang XQ. Effect of RNAi silencing of theWT1 gene on the apoptosis of human hepatocellular carcinoma cell hepG2[J]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, 2010, 26(8): 771-773.
[18]Andersson C, Oji Y, Ohlson N, et al. Prognostic significance of specific anti-WT1 IgG antibody level in plasma in patients with ovarian carcinoma[J]. Cancer Med, 2014, 3(4): 909-918.
[19]邢冲云, 高申孟, 梁彬, 等. 实时荧光定量PCR检测急性髓系白血病患者WT1基因表达及其临床意义[J]. 温州医学院学报, 2011, 6(4): 527-530.